GSK, MMV Announce Commencement of Phase III Programme of Tafenoquine for Plasmodium Vivax Malaria

By: via Benzinga
GlaxoSmithKline (NYSE: GSK) and Medicines for Malaria Venture (MMV) today announced the start of a phase III global programme to ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.